Join us Thursday, May 16th at 7 pm ET/4 pm PT
Learn about a ROCK2 Inhibitor medication being developed by Ovid Therapeutics and Graviton Bioscience with the potential to have a significant impact on the treatment of Cavernous Malformation. Join us for a conversation with Amy Melsaether, MD, Chief Medical Officer, Graviton BioScience, and Jeremy Levin, CEO, Ovid Therapeutics.